IDH2 and glioma: Highly reliable antibodies for IDH1 R132H, which constitutes approximately 90% of all IDH mutations in gliomas [3,15], are commercially available and widely used [16,17], but antibodies for other IDH1 and IDH2 mutant proteins are less widely available [18].